← Leaderboards
Tomas G Neilan
Massachusetts General Hospital
$7,988,541
Attributed
$10,928,926
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,928,926 · 5
By mechanism
R01$9,894,884 · 3
K24$749,230 · 1
T32$284,812 · 1
Top collaborators
- Marielle Scherrer-Crosbie5 shared
- Markella V. Zanni4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Steven Kyle Grinspoon$75,757,679
- Guillermo J. Tearney$42,608,505
- Ahmed A Tawakol$9,912,063
- Brett E Bouma$16,028,207
- Udo Hoffmann$17,171,978
Others in their field
Top investigators on “Cardiac”
- Judith S Hochman · New York University School Of Medicine$110,228,771
- Anne Christine Gelijns · Icahn School Of Medicine At Mount Sinai$69,868,084
- Rose A Gubitosi-Klug · Case Western Reserve University$61,225,818
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,141,827
- Joseph C Wu · Stanford University$53,027,789
- Pamela Susan Douglas · Duke University$51,506,531
Research focus
CardiacClinical ResearchBiological MarkersImageMalignant NeoplasmsRandomizedInnovationTroponinCardiovascular SystemCoronary FibrosisHeart FailureParticipantMyocardialMortalityImaging TechniquesMagnetic Resonance ImagingFibrosisRisk FactorsBasePersonsCardiotoxicityMagnetic ResonanceAttenuationHeart Function
Grant awards (20)
Immune checkpoint inhibitors and accelerated coronary atherosclerosis$1,023,526
R01 · FY2025 · HL · contact PI
Cardiovascular Diseases among Patients with Cancer and Patients living with HIV$133,685
K24 · FY2025 · HL · contact PI
Immune checkpoint inhibitors and accelerated coronary atherosclerosis$971,495
R01 · FY2024 · HL · contact PI
Cardiovascular Diseases among Patients with Cancer and Patients living with HIV$123,109
K24 · FY2024 · HL · contact PI
Immune checkpoint inhibitors and accelerated coronary atherosclerosis$977,964
R01 · FY2023 · HL · contact PI
Cardiovascular Diseases among Patients with Cancer and Patients living with HIV$123,109
K24 · FY2023 · HL · contact PI
Immune checkpoint inhibitors and accelerated coronary atherosclerosis$1,041,129
R01 · FY2022 · HL · contact PI
Cardiovascular Diseases among Patients with Cancer and Patients living with HIV$123,109
K24 · FY2022 · HL · contact PI
Cardiovascular Diseases among Patients with Cancer and Patients living with HIV$123,109
K24 · FY2021 · HL · contact PI
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins$659,315
R01 · FY2020 · HL · contact PI
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines$631,959
R01 · FY2020 · HL · contact PI
Cardiovascular Diseases among Patients with Cancer and Patients living with HIV$123,109
K24 · FY2020 · HL · contact PI
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins$663,909
R01 · FY2019 · HL · contact PI
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines$631,676
R01 · FY2019 · HL · contact PI
Cardiac MR and CT Research$284,812
T32 · FY2019 · HL · contact PI
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins$683,840
R01 · FY2018 · HL · contact PI
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines$628,461
R01 · FY2018 · HL · contact PI
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins$708,470
R01 · FY2017 · HL · contact PI
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines$619,549
R01 · FY2017 · HL · contact PI
STOP-CA: Statins to prevent Cardiotoxicity from Anthracyclines$653,591
R01 · FY2016 · HL · contact PI